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ABSTRACT 
Background Elderly psoriasis (PsO) patients are a growing population, frequentely 
excluded from clinical trials and described as a high-risk group for adverse events. 
Our aim is to describe safety and clinical impact of systemic PsO therapy in elderly 
patients treated with methotrexate or biologic drugs. 
Methods  Elderly patients (≥65 years-old) receiving systemic PsO treatment at a 
reference centre, registered to DERMA.PT, were grouped according to current 
therapy – patients receiving methotrexate (MTX) and patients receiving biologic 
drugs (BIO). Patients’  epidemiological and clinical characteristics were described. 
Adverse events of previous and current therapies were registered and compared 
according to treatment at that time. Comorbidities were analyzed within the elderly 
groups and compared to non-elderly patients also receiving systemic therapy. 
Results 43 (20.0%) of 215 registered patients were elderly, 23 receiving 
methotrexate (MTX) and 20 receiving biologic drugs (BIO) with similar 
characteristics. BIO patients registered a significantly higher frequency of previous 
treatments than MTX patients (BIO 75.0% vs. MTX 8.7%, P < 0.001). Total number 
of adverse events in both groups was not different (P < 0.101). In general, elderly 
patients had higher frequency of comorbidities than non-elderly patients.  
Conclusions Total number of adverse events was similar between MTX and BIO 
patients, the majority of which were non-serious and merely required dose 
adjustments. These results are reassuring, contributing to the demystification of the 
use of systemic treatments in the elderly and providing the best possible care to this 
growing group of patients.
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INTRODUCTION 
Psoriasis (PsO) is a chronic inflamatory skin disease that affects 2-3% of the global 
population.  Besides the envolvement of the skin, patients may also have Psoriatic 
Arthritis (PsA) and high prevalence of cardiovascular comorbidities, such as 
dyslipidaemia and hypertension. Some studies have demonstrated that PsO is an 
independent risk factor for the development of diabetes and other components of 
metabolic syndrome, indirectly serving as a risk factor for cardiovascular disease. 1 
The typical pattern of remission and recurrence of PsO depends on several 
precipitant factors such as emotional and physical stress, leading to low self-esteem, 
anxiety and depression.2 
PsO can be diagnosed at any age, typically in a bimodal pattern: in young adults (15-
25 years-old) and later, between 50 and 60 years-old.3 The distinction between 
early-onset (<40 years-old) and late-onset (≥40 years-old) disease is also frequently 
mentioned due to differences in genetic components and clinical presentation4, but 
without current recognised practical application on a daily basis.  
Population ageing has been an increasing trend in Europe, particularly in Portugal, 
where 19% of the population was ≥65 years-old in 2011.5 The present scenarios 
pose challenges for the therapeutic approach for chronic inflammatory diseases, such 
as PsO. 
Nowadays, patients have been able to maintain a longstanding state of remission 
due to the introduction of classic or biotechnological systemic drugs. It is well-
documented in several studies including non-elderly (<65 years-old) patients with 
PsO, PsA, Rheumatoid Arthritis (RA) and Ankylosing Spondylitis (AS).6 However, the 
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elderly (≥ 65 years-old) are a subset of patients frequently excluded from clinical 
trials due to the higher number of comorbidities and polymedication, which pose 
them as a high-risk group for drug interactions and serious adverse events. Thus, 
there is lack of information about safety and effectiveness of avaliable treatments for 
PsO in the elderly, particularly about systemic drugs. Furthermore, some studies 
have demonstrated that dermatologists are still very reluctant to medicate these 
patients with systemic drugs, narrowing their treatment options to topical agents, in 
order to minimize possible adverse events, but compromising treatment effectiveness 
and only achieving a moderate control of the disease.7  
Recently, progress has been made with several observational studies in older 
patients.3,8-11 Nevertheless, clinical trials specifically testing systemic drugs in the 
elderly are scarse, creating an obstacle in reaching consensus regarding drug doses 
and possible therapeutic combinations, in order to improve life quality and control of 
the disease in this population. 
Our aim is to describe safety and clinical impact of systemic PsO therapy, comparing 
elderly patients treated with methotrexate and elderly patients treated with 
biotechnological drugs. 
	 5	
MATERIAL AND METHODS 
This retrospective observational study is designed to be based on the portuguese 
registry database for psoriatic diseases, DERMA.PT. Data collection from this 
platform assures a real-life scenario, data quality and fast data collection. The use of 
DERMA.PT information is authorised by the local ethics commitee, following 
International Council for Harmonisation (ICH) Good Clinical Practice (GCP) guidelines, 
according to the Helsinki Declaration and ensuring maximum confidentiality. We 
collected data until the 15th of March 2017. 
Since the portuguese age of retirement is 65 years-old, we defined elderly patients 
as individuals who are 65 years-old or over. We selected elderly patients with 
moderate to severe PsO, registered to DERMA.PT, receiving isolated biotechnological 
drugs (etanercept, adalimumab, ustekinumab, infliximab, secukinumab or 
golimumab) or methotrexate, at Centro Hospitalar São João (CHSJ), Porto, Portugal, 
in March 2017. Our aim is to compare two subgroups of elderly individuals: patients 
treated with methotrexate (MTX) and patients treated with any isolated 
biotechnological drug (BIO). We exported information from DERMA.PT concerning 
patient characteristics (gender, date of birth, date of diagnosis of PsO, weight, 
height, type of PsO and comorbidities), previous and current systemic treatments, 
registered reason of withdrawl and adverse events. All events were considered, 
including ones caused by previous systemic treatments that are now terminated, and 
classified as non-severe adverse events (NSAE), with minor implications for the 
patient, not requiring any specific treatment or merely dose adjustments, and severe 
adverse events (SAE), if they were tumours, life-threatening events or motivated 
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hospitalization and/or surgery. Current age, age of onset and length of disease were 
calculated, based on date of birth and date of diagnosis of PsO. Body mass index 
(BMI) was calculated using current weight and height of each individual. Patients 
were classified as obese, overweight and normal BMI according to World Health 
Organization (WHO) definition.12 Our definition of major cardiovascular events 
(MACE) included episodes of acute myocardial infaction (AMI), stroke, transient 
ischemic attack (TIA), deep (DVT) vein thrombosis and pulmonary embolism (PE). 
Baseline and current disease activity were measured through the Psoriasis Area 
Severity Index (PASI), Body Surface Area (BSA) and Dermatology Quality of Life 
Index (DLQI). 
Information from non-elderly patients (<65 years-old) regarding comorbidities was 
also collected, in order to ascertain differences between the two age groups. 
5 non-elderly patients (2 females, 3 males) were excluded from this study because 
they had withdrawled systemic treatment during 2016. 3 elderly patients were 
excluded from statistical analysis because they are currently receiving treatment with 
methotrexate in association with a biologic drug. 
Quantitative data are expressed as means and standard deviations (SD), while 
qualitative data are expressed as n (%). Means were compared using Student’s t-test 
and frequencies with the χ2 test or Fisher’s exact test when necessary. A P < 0.05 
was considered as statistically significant. Statistical analyses were computed with 
IBM® SPSS® Statistics, Version 24.  
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RESULTS 
CHSJ had two hundred twenty-three patients registered to DERMA.PT in March 2017, 
two hundred fifteen of which were eligible for our study. Eighty-two females (38.1%) 
and one hundred thirty-six males (63.2%), one hundred seventy-two non-elderly 
(80.0%) and forty-three elderly patients (20.0%).  
Our study population included thirty males (79.8%) and thirteen females (30.2%), 
with mean age of 71.0 ± 4.7 years-old. Twenty-three patients were receiving 
systemic treatment with methotrexate (MTX group) and twenty with biologic drugs 
(BIO group). Within BIO patients, eight were receiving treatment with etanercept, 
eight with adalimumab, three with ustekinumab and one with secukinumab (Table 
1). 
Differences in mean age between MTX and BIO patients (70.6 ± 5.0 vs. 71.4 ± 4.5) 
were not statistically significant (P < 0.566), as well as age of onset (42.0 ± 19.5 vs. 
39.7 ± 15.1, P < 0.672) and length of disease (28.2 ± 18.1 vs. 31.4 ± 14.6, P < 
0.533) (Table 1). In both groups, the most frequent main clinical aspect of PsO was 
the presence of PsA (56.5% MTX vs. 75% BIO, P < 0.205). Body mass index (BMI) 
was not considered different between MTX and BIO patients (P < 0.775). 43.4% of 
MTX patients were obese and 60.0% of BIO patients were overweight. No 
differences were found between both groups regarding comorbidities. Hypertension 
(65.2%) and dyslipidaemia (65.2%) were the most common associated conditions in 
MTX patients and PsA (75.0%) and hypertension (65.0) were the most frequent 
comorbidities within BIO patients (Table 1). All comorbidities except ungueal 
dystrophy (22.7% vs. 11.6%), were more frequent in the elderly group, compared to 
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non-elderly individuals. On the one hand, cardiac valvular disease, Crohn’s disease, 
hepatitis B and hepatitis C each had 1 case registered in the non-elderly group. On 
the other hand, ulcerative colitis had 1 case registered in the elderly group. (Table 2) 
Considering previous therapies, the majority of patients in the BIO group had already 
been treated with other systemic drugs (MTX 8.7% vs. BIO 75.0%, P < 0.001). 
Fifteen BIO patients had tried at least one drug and two patients had experimented 
with 3 previous treatments. Twenty-one patients (91.3%) from the MTX group were 
naïve for previous systemic therapies (Table 1). 
Both groups included patients with moderate to severe PsO with high baseline PASI, 
BSA and DLQI. However, there were statistically significant differences between both 
groups. BIO patients generally had higher baseline PASI (21.1 ± 13.0 vs. 12.3 ± 5.4, 
P < 0.013) and DLQI (15.8 ± 3.6 vs. 12.9 ± 3.3, P < 0.025), and lower current DLQI 
(0.8 ± 0.8 vs. 2.3 ± 2.6, P < 0.026) and BSA (1.0 ± 1.1 vs. 7.3 ± 9.5, P < 0.008). 
(Table 1) 
A total of seventy-three adverse events were registered, thrity in the MTX group (23 
NSAE and 7 SAE) and forty-three in the BIO group (34 NSAE and 9 SAE), without 
statistically significant differences between total events in both groups (P < 0.101). 
MTX patients registered a higher proportion of SAE than BIO patients. Both groups 
registered a minimum of zero events, with maximum of six events in MTX patients 
and seven events in BIO patients (Table 3). It should be noted the existence of 7 
cases in MTX-treated patients and 3 cases in BIO-treated patients without any 
reports of adverse events. Distribution of adverse events according to active 
treatment at the moment of occurrence is presented in Table 4. For a total of 
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seventy-three reported adverse events, thirty-five (47.9%) occurred with 
methotrexate, seventeen (23.3%) with adalimumab, eleven (15.1%) with 
etanercept, six (8.2%) with ustekinumab and the remainder divided by infliximab 
(1.4%), methotrexate+adalimumab (1.4%) and methotrexate+infliximab (2.7%). 
The most frequent event was hepatotoxicity with twenty-five (34.2%) reports, 
followed by viral respiratory infections with twelve (16.4%) reports and bacterial 
respiratory infections with six (8.2%) reports. 
At last, it is worth mentioning the three elderly patients, all male with ages 
comprised between 68 and 76 years-old, receiving treatment with an association of 
low doses of methotrexate and standard doses of biologic drugs, one of etanercept, 
one of adalimumab and one of infliximab. It is interesting to note that only one had a 
serious adverse event that conditioned hospitalization, in this case a fracture of the 
femur during treatment with etanercept in 2014. Overall, the three had a total of 5 
adverse events, 4 of which were non-serious (1 episode of hepatotoxicity and 3 
episodes of viral respiratory infection). All three have hypertension, PsA and are 
overweight. 
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COMMENT 
Systemic treatments, particularly biologic drugs, have gradually become an important 
therapeutic option in the management of psoriatic patients. Safety and efficacy of 
systemic drugs are well-established in several studies performed with rheumatology 
patients.6,13-18 However, information about psoriatic patients is still scarce19-25 and 
elderly individuals continue to be frequently excluded from clinical trials, incurring the 
risk of being largely undertreated regarding their condition. 
In the present study, our population from DERMA.PT is composed by two hundred 
fifteen patients, with 20% of elderly individuals. In spite of being a small size 
sample, the proportion of patients aged equal and over 65 years-old is double the 
ones described in other similar european studies, in France and Spain, where elderly 
patients represent 9.5% and 9.8%, respectively, of the population.3,10 It is also 
worth mentioning that this proportion of older patients goes in line with the current 
portuguese population, which in 2011 had 19% of elderly individuals.5 The 
distribution according to gender shows a higher number of male patients (63.2%), 
even within elderly patients (79.8%), which goes against some studies that describe 
a higher prevalence of elderly female patients.3,10  
Regarding comorbidities, we observed that older patients tend to have more 
associated diseases than younger ones. The only exception is ungueal dystrophy, 
which in our population was more frequent in the non-elderly group. 20-30% of 
psoriatic patients tend to develop PsA after approximately 10 years of disease.26 Both 
MTX and BIO groups had higher prevalences of PsA compared to younger 
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individuals, with a total of 28 (65.1%) elderly and 78 (45.3%) non-elderly patients 
affected by this comorbidity.  
PsO is considered an independent risk factor for the development of several 
components of metabolic syndrome such as dyslipidaemia, hypertension, diabetes 
and obesity.1 Phan et al. reported a higher prevalence of these conditions in 
association with greater age.22 Age alone is a well-known contributor for numerous 
disorders, including cancer and cardiovascular disease. Accordingly, it was not 
surprising that these comorbidities had higher prevalence in the elderly group in the 
present study (Table 4). 
The higher incidence of comorbidities in elderly patients is generally assumed as a 
risk factor for adverse events, but it is still unclear to what extent should we exclude 
these patients from systemic treatment because of their associated conditions. In our 
study, we found no differences between total number of adverse events in MTX and 
BIO patients (P < 0.101), despite the fact that comorbidities were, in general, more 
frequent in elderly patients. Furthermore, when analyzing the incidence of adverse 
events in older individuals, some studies state that elderly and non-elderly patients 
have similar rates of total reported adverse events, with a higher incidence of severe 
ones.10,14 This could possibly become a turning point in management of moderate to 
severe PsO in older patients. However, across the globe, guidelines for clinical 
practice regarding systemic therapy for PsO are not uniform and depend on 
geographical location.27 Consequentely, in light of limited reliable information, 
dermatologists continue to be reluctant to medicate elderly patients with systemic 
drugs, in fear of adverse events and drug interactions, leading to undertreatment 
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and moderate control of the disease.7 Surely, adverse effects of treatment should 
always be considered when deciding whether to prescribe systemic drugs, 
notwithstanding each patient is unique and should be managed according to their 
illness and comorbidities in association with follow-up program with close monitoring 
of patients. In both MTX and BIO patients, the majority of adverse events were non-
serious and were treated with small dose adjustments or short periods of 
discontinuation, in order to minimize the impact on PsO therapy. This information is 
reassuring and testifies to the ease of managing side effects if the patient monitoring 
program is effective. 
In regard to past systemic therapies, BIO patients registered a significantly higher 
frequency of previous treatments than MTX patients (BIO 75.0% vs. MTX 8.7%, P < 
0.001). However, this is in agreement with the therapeutic escalation performed in 
our institution. 
Systemic therapy is recommended in cases of moderate to severe PsO, with PASI, 
BSA and DLQI scores reflecting an active disease, with a negative impact on the 
patient’s psychological state and ability to perform activities of daily living.2,28,29 It is 
important to emphasize that elderly patients may have as serious a disease as non-
elderly people, benefiting greatly from systemic treatment, with higher number of 
longstanding remissions and longer periods between relapses, as already well-
established for other age groups and other chronic diseases, such as RA7,8,10,11,18,24, 
and our results turned out to reflect these aspects (Table 1). 
This  study  might  have  some  characteristic  limitations  of  retrospective  studies,  
such  as:  selection  bias (both  patient  and  treatment  selection  bias),  information  
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bias,  confounding  (absence  of  data  on  potential confounding factors if the data 
was not recorded in the past), ascertainment/enrollment bias, lost to follow-up and 
censored observations. 
Considering the aging of the population in developed countries, it becomes even 
more important to evaluate the suffering of the elderly with certain chronic illnesses 
like PsO. As in other diseases such as hypertension and diabetes, in which therapies 
are already targeted for a specific age group and its comorbidities, it is necessary to 
optimize the treatment of the elderly also in PsO, taking into account the whole set 
of associated diseases. Our results are reassuring considering that older patients 
tend to have more comorbidities and effectively are at greater risk of drug 
interactions due to polimedication. Along with other similar conclusions from recent 
studies3,7,10, this could become a turning point in management of moderate to severe 
PsO in the elderly, contributing to the demystification of the use of systemic 
treatments in these conditions and providing the best possble care and quality of life 
to this growing group of patients. 
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Table 1 – Epidemiological, clinical characteristics, treatments and comorbidities of 
elderly psoriatic patients – MTX group vs. BIO group 
 MTX 
n=23 
BIO 
n=20 
P-value 
Length of treatment (months), mean ± SD  52.6 ± 34.1 59.3 ± 37.6  
Age (years), mean ± SD 70.6 ± 5.0 71.4 ± 4.5 0.566 
Gender, n (%) 
     Male 
 
16 (69.6) 
 
14 (70.0) 
0.975 
Age of onset (year), mean ± SD 42.0 ± 19.5 39.7 ± 15.1 0.672 
Length of disease (year), mean ± SD 28.2 ± 18.1 31.4 ± 14.6 0.533 
Main clinical aspect of PsO, n (%) 
     Plaque PsO 
     PsA, n (%) 
 
10 (43.5) 
13 (56.5) 
 
5 (25.0) 
15 (75.0) 
0.205 
BMI, n (%) 
     Normal (18.50 ≤ BMI < 25 kg/m2) 
     Overweight (≥ 25 kg/m2) 
     Obesity (≥ 30 kg/m2) 
 
4 (17.3) 
9 (39.1) 
10 (43.4) 
 
2 (10.0) 
12 (60.0) 
6 (30.0) 
0.775 
Disease activity, mean ± SD 
     Baseline PASI 
     Current PASI 
     Baseline DLQI 
     Current DLQI 
     Baseline BSA 
     Current BSA 
 
12.3 ± 5.4 
3.8 ± 3.6 
12.9 ± 3.3 
2.3 ± 2.6 
20.4 ± 10.6 
7.3 ± 9.5 
 
21.1 ± 13.0 
2.0 ± 2.4 
15.8 ± 3.6 
0.8 ± 0.8 
40.4 ± 32.5 
1.0 ± 1.1 
 
0.013** 
0.078 
0.025** 
0.026** 
0.051 
0.008** 
Previous systemic treatment, n (%) 
     Yes 
     No 
 
2 (8.7) 
21 (91.3) 
 
15 (75.0) 
5 (25.0) 
<0.005* 
Number of previous treatments, n (%) 
     0 
     1 
     2 
     3 
 
21 (91.3) 
2 (8.7) 
0 (0.0) 
0 (0.0) 
 
5 (30.4) 
10 (47.8) 
3 (13.0) 
2 (8.7) 
<0.005*** 
Current treatment, n (%) 
     Methotrexate 
 
23 (100) 
 
0 (0.0) 
 
	 19	
     Etanercept 
     Adalimumab 
     Infliximab 
     Ustekinumab 
     Secukinumab 
     Golimumab 
0 (0.0) 
0 (0.0) 
0 (0.0) 
0 (0.0) 
0 (0.0) 
0 (0.0) 
8 (40.0) 
8 (40.0) 
0 (0.0) 
3 (15.0) 
1 (5.0) 
0 (0.0) 
Comorbidities, n (%) 
     PsA 
     Diabetes 
     Hypertension 
     Dyslipidaemia 
     Obesity 
     MACE 
     Skin cancer 
     Non-skin cancer 
 
13 (56.5) 
5 (21.7) 
15 (65.2) 
15 (65.2) 
10 (43.4) 
2 (8.7) 
2 (8.7) 
1 (4.3) 
 
15 (75.0) 
4 (20.0) 
13 (65.0) 
10 (50.0) 
6 (30.0) 
1 (5.0) 
3 (15.0) 
1 (5.0) 
 
*Chi-Square Test, **ANOVA, ***Mann-Whitney U test 
PsA, Psoriatic Arthritis; MACE, Major Cardiovascular Events; PASI, Psoriasis Area Severity Index; BSA, Body Surface Area; DLQI, 
Dermatology Quality of Life Index 
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Table 2 – Comorbidities in elderly and non-elderly patients, n (%) 
 
Non-Elderly (<65 yo) 
n=172 
Elderly (≥65 yo) 
n=43 
PsA 78 (45.3) 28 (65.1) 
Obesity 32 (18.6) 16 (37.2) 
Hypertension 45 (26.2) 28 (65.1) 
Diabetes 13 (7.6) 9 (20.9) 
Dyslipidaemia 50 (29.1) 25 (58.1) 
Ischaemic cardiomyopathy 1 (0.6) 5 (11.6) 
Chronic heart failure 0 (0.0) 2 (4.6) 
Atrial Fibrillation 1 (0.6) 2 (4.6) 
Valvular heart disease 1 (0.6) 0 (0.0) 
Ulcerative colitis 0 (0.0) 1 (2.3) 
Crohn’s disease 1 (0.6) 0 (0.0) 
Chronic hepatopathy 17 (9.9) 5 (11.6) 
Hepatitis B 1 (0.6) 0 (0.0) 
Hepatitis C 1 (0.6) 0 (0.0) 
Dactylitis 8 (4.6) 4 (9.3) 
Ungueal dystrophy 39 (22.7) 5 (11.6) 
Skin cancer 1 (0.6) 5 (11.6) 
Non-skin cancer 1 (0.6) 2 (4.6) 
MACE 0 (0.0) 3 (7.0) 
Chronic pulmonary disease 10 (5.8) 7 (16.3) 
Renal disease 5 (2.9) 7 (16.3) 
Depression/Anxiety 7 (4.1) 2 (4.6) 
Hypothyroidism 0 (0.0) 2 (4.6) 
Hyperuricemia 3 (1.7) 4 (9.3) 
Other skin disorders 4 (2.3) 4 (9.3) 
PsA, Psoriatic Arthritis; MACE, Major Cardiovascular Events 
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Table 3 – Frequency and severity of adverse events in MTX and BIO patients 
 MTX 
n= 23 
BIO 
n=20 
P-value 
Total events, n (%) 30 (100) 43 (100)  
Number of events, mean ± SD  
Minimum  
Maximum 
1.3 ± 1.5 
0 
6 
2.2 ± 1.8 
0 
7 
0.101 
Severity, n (%) 
     NSAE 
     SAE 
 
23 (76.7) 
7 (23.3) 
 
34 (79.1) 
9 (20.9) 
 
NSAE, Non-severe adverse events; SAE, Severe adverse events 
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Table 4 – Number of adverse events according to active systemic treatment at the 
time of occurrence, n (%) per total number of events. 
Mtx, Methotrexate; Eta, Etanercept; Ada, Adalimumab; Ustek, Ustekinumab; Inf, Infliximab 
HF, Heart Failure; GI, Gastrointestinal; MACE, Major Cardiovascular Events 
 Mtx Eta Ada Inf Ustek Mtx+
Ada 
Mtx+
Inf 
Total 
 Hepatotoxicity 19 (26.0) 2 (2.7) 2 (2.7) 0 (0.0) 2 (2.7) 0 (0.0) 0 (0.0) 25 (34.2) 
Skin Infection 
     Bacterial 
    Fungal 
    Viral 
 
0 (0.0) 
3 (4.1) 
1 (1.4) 
 
0 (0.0) 
0 (0.0) 
1 (1.4) 
 
1 (1.4) 
1 (1.4) 
1 (1.4) 
 
0 (0.0) 
0 (0.0) 
0 (0.0) 
 
0 (0.0) 
0 (0.0) 
0 (0.0) 
 
0 (0.0) 
0 (0.0) 
0 (0.0) 
 
0 (0.0) 
0 (0.0) 
0 (0.0) 
 
1 (1.4) 
4 (5.5) 
3 (4.1) 
Respiratory 
infection 
     Bacterial 
    Viral 
 
 
1 (1.4) 
0 (0.0) 
 
 
1 (1.4) 
5 (6.8) 
 
 
2 (2.7) 
4 (5.5) 
 
 
0 (0.0) 
0 (0.0) 
 
 
1 (1.4) 
2 (2.7) 
 
 
1 (1.4) 
0 (0.0) 
 
 
0 (0.0) 
1 (1.4) 
 
 
6 (8.2) 
12 (16.4) 
GI infection 
     Fungal 
 
1 (1.4) 
 
0 (0.0) 
 
1 (1.4) 
 
0 (0.0) 
 
0 (0.0) 
 
0 (0.0) 
 
0 (0.0) 
 
2 (2.7) 
Acute biliary 
pancreatitis 
1 (1.4) 1 (1.4) 1 (1.4) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 3 (4.1) 
Skin cancer 0 (0.0) 1 (1.4) 1 (1.4) 0 (0.0) 1 (1.4) 0 (0.0) 0 (0.0) 3 (4.1) 
Non-skin 
cancer 
0 (0.0) 0 (0.0) 1 (1.4) 1 (1.4) 0 (0.0) 0 (0.0) 0 (0.0) 2 (2.7) 
MACE 0 (0.0) 0 (0.0) 1 (1.4) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (1.4) 
Bone fracture 1 (1.4) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (1.4) 
Hemoperitoneum 1 (1.4) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (1.4) 
Appendicitis 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (1.4) 1 (1.4) 
GI intolerance 1 (1.4) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (1.4) 
Head injury 1 (1.4) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (1.4) 
Cytopenia 2 (2.7) 0 (0.0) 1 (1.4) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 3 (4.1) 
Pulmonary 
toxicity 
1 (1.4) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (1.4) 
Pyelonephritis 1 (1.4) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (1.4) 
Acute HF 1 (1.4) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (1.4) 
Total 35 (47.9) 11 (15.1) 17 (23.3) 1 (1.4) 6 (8.2) 1 (1.4) 2 (2.7) 73 (100) 
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1. ABOUT IJD 
Published monthly, the International Journal of Dermatology (IJD) is specifically designed to 
provide dermatologists around the world with a regular, up-to-date source of information on 
all aspects of the diagnosis and management of skin diseases. Accepted articles regularly 
cover clinical trials, education, morphology, pharmacology and therapeutics, case reports, 
and reviews. Additional features include tropical medicine reports, news, correspondence, 
and proceedings and transactions.  
IJD is guided by a distinguished, international editorial board and emphasizes a global 
approach to continuing medical education for physicians and other providers of health care 
with a specific interest in problems relating to the skin.  
2. MANUSCRIPT CATEGORIES 
IJD invites the following types of submission:  
Case Report* 
A report of 400–600 words, illustrated by no more than three illustrations. This category 
offers a means for rapid communication about a single subject.  
Clinical Trial 
An article of 700–1200 words concerning a drug evaluation. This category provides rapid 
publications and is meant to be a succinct presentation with a minimum of graphs and tables.  
Commentary* 
An editorial 700–1200 words in length with approximately five references. The author may 
express his or her opinion without complete documentation.  
Clinicopathological Challenge* 
A photographic essay that includes both a clinical and a pathological photograph in color. The 
diagnosis and legends for the photographs should be listed after the references in the article. 
The article should be no more than 2 pages in length and contain 4-5 references..  
Correspondence* 
Letters to the editor and short notes. Contributions should not exceed 600 words, two 
figures, and 10 references. In order to offer rapid dissemination of accepted manuscripts, 
Correspondence items will be published online-only. Online-only correspondence items are 
assigned to an issue of the journal, but are excluded from the print edition. Online-only 
correspondence items are e-paginated and are fully citable and indexable.  
Dermatological Surgery 
An article relating to the surgical aspects of treatment. Article types may include Review, 
Report or Case Report Format.  
Education 
An article about the methodology of curriculum and instruction in dermatology, about 2500 
words.  
Morphology* 
A photographic essay that emphasizes one or two photographs, in color. There should be 
accompanying text and references, but the entire article will appear on one printed page.  
On a Human Scale* (by invitation only) 
An article that relates to social, economic, cultural, artistic and humanitarian aspects of 
medicine. The length of the article should not exceed 1200 words including a short summary 
of the topic addressed. A brief author biography and photo should be submitted with the 
article. If you have a topic that you feel would fit nicely in this section, please send a note to 
ijdermatol@mayo.edu for approval to submit.  
Pharmacology and Therapeutics 
An article relating to the treatment of diseases and to the pharmacology of dermatologically-
related drugs. (Can include Clinical Trials, Reviews, Reports, Case Reports and 
Correspondence. The latter is preferred for reports of adverse drug reactions.) When 
referring to a drug, please use the generic name approved by the United States Food and 
Drug Administration or recognized as the United States Adopted Name. At the end of the 
manuscript, please list the American Trade names.  
Reminiscence 
An article on the history of dermatology or skin diseases; also a biographic account of an 
historic or noteworthy figure in dermatology.  
Report 
An original article including, whenever possible, an Introduction, Materials and Methods or 
Case Report(s), Results, Comment, and References. A Structured Abstract of not more than 
250 words must be included and should consist of four paragraphs labeled Background, 
Methods, Results, and Conclusions. Also, it should describe the problem studied, how the 
study was performed, the main results, and what the author(s) concluded from the results. 
The article should range from 2500-3000 words.  
Review 
A major didactic article that clarifies and summarizes the existing knowledge in a particular 
field. It should not be an exhaustive review of the literature, and references should not 
exceed 50 in number. Tables, diagrams, and selected figures are often helpful and prefered. 
The length is left to the judgment of the author, although it generally should not exceed 5000 
words. Topics may include updates in clinically relevant basic science and cutaneous biology. 
A list of 10 questions should be listed at the end of the article to provide additional 
educational challenge to the reader. An abstract is required, though it need not be 
structured.  
Tropical Medicine Rounds 
An article dealing with the diseases and special problems encountered by dermatologists 
working in the tropics. Article submissions should follow the Report or Case Report format.  
Updates in Medicine 
By invitation only. This contribution to the journal should be 700–1200 words in length with 
sufficient references to document important points. It is not essential that the contribution be 
heavily referenced as it is meant to serve as an update for dermatologists in various fields of 
medicine and is not portrayed to be an extensive or exhaustive review of the literature. 
However, it would be very helpful if pertinent and salient references are included, not only for 
documentation purposes, but also for additional reading.  
Medical Genetics 
Report, Review or Case Report format should be followed.  
*No abstract required 
3. SUBMISSION OF MANUSCRIPTS 
Submissions should be made online at the IJD ScholarOne Manuscripts site (formerly known 
as Manuscript Central). New users should first create an account (do not upload document 
files at this time). Once a user is logged onto the site, submissions should be made via the 
Author Center.  
Revised manuscripts must be submitted as revisions as directed by the ScholarOne website. 
Do not resubmit a revision as a new manuscript as this may result in re-review and 
considerable delay. The revision should be complete and contain all the tables and figures. 
Do not resubmit the original manuscript with your revision.  
Submission of a manuscript will be held to imply that it contains original unpublished work 
and is not being submitted for publication elsewhere at the same time. The author must 
supply a full statement to the Editor about all submissions and previous reports that might be 
regarded as redundant or duplicate publication of the same or very similar work.  
4. PREPARATION OF MANUSCRIPTS 
Manuscripts must be written in English and must comply with these instructions in every 
detail.  
Text should be supplied in a word processed format such as Microsoft Word for Windows. 
Charts and tables are considered textual and should be supplied in the same format. Figures 
(illustrations, diagrams, photographs) should be supplied in gif, jpeg, tif or eps format.  
All manuscripts must be typed in 12 pt font with lines double spaced and margins of at least 
2.5 cm.  
Abbreviations must be defined when first used, both in the abstract and in the main text.  
Manuscripts must be as succinct as possible. Text must comply with the word and figure 
limits defined in Section 2. If authors consider that a manuscript should not conform to the 
limits specified, exceptionally good reasons must be clearly provided in a cover letter 
accompanying the submission. Repetition of information or data in different sections of the 
manuscript must be carefully avoided.  
Manuscripts should, where appropriate, include: 
Title Page 
The first page of all manuscripts should contain the following information: 
1) the title of the paper 
2) surnames (family names),initials of each author, and their degree (if any) 
3) name of the institution(s) at which the research was conducted 
4) name, address, telephone number and email address of corresponding author 
5) manuscript word count (excluding abstract and references), table and figure count 
7) any conflict of interest disclosures (see Section 5) 
8) a running head not exceeding 50 characters  
Abstracts 
Authors submitting Reports should note that structured abstracts (maximum 250 words) are 
required. The structured abstract should adopt the format: Background, Methods, Results, 
Conclusions.  
Review articles require abstracts (maximum 250 words) but they need not be structured.  
Abstracts should not contain citations. 
Text 
This should in general, but not necessarily, be divided into sections with the headings: 
Abstract, Introduction, Materials and Methods, Results, Discussion, Acknowledgements, 
References, Tables, Table and figure legends. Figures should be submitted as separate files. 
The acknowledgements should include a statement of all funding sources that supported the 
work.  
Please submit the full text of the manuscript, including the abstract, references, tables and 
legends as a single document. The title page may be included as page 1 of the main 
manuscript document or can be uploaded as a separate file, but must be included.  
Tables and Figures 
Tables should not be inserted in the appropriate place in the text but should be included at 
the end of the manuscript, each on a separate page.  
Figures (illustrations, diagrams, photographs) should be supplied in gif, jpeg, tif or eps format 
and submitted as separate electronic files.  
Tables and figures should be referred to in text as follows: Fig. 1, Figs. 2–4; Table 1, Tables 
2 and 3. The place at which a table or figure is to be inserted in the printed text should be 
indicated clearly on a manuscript. Each table and/or figure must have a legend that explains 
its purpose without reference to the text. Where a figure has more than one panel, each 
panel should be labelled in the top left-hand corner using lower case letters in parentheses 
i.e. ‘(a)’, ‘(b)’ etc., and a brief description of each panel given in the figure legend. When 
using histology figures, the stain type and magnification level must be included in the legend.  
Only figures of excellent quality will be considered for publication. The Journal will publish 
color photographs free of charge subject to editorial approval. When an individual is 
identifiable in a photograph written permission must be obtained (see Section 5 ‘Ethics’ 
below).  
Authors are themselves responsible for obtaining permission to reproduce previously 
published figures or tables.  
References 
References should be in Vancouver format and appear as consecutive, unbracketed 
superscript numbers in the text, e.g. ‘in our previous reports1,2 and those of Smith et al.3–5’ 
and should be listed numerically in the reference list at the end of the article.  
Format references as below, using standard (Medline) abbreviations for journal titles. When 
there are more than four authors, include the first three authors followed by et al.  
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Ethics 
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use of laboratory animals was followed. A statement describing explicitly the ethical 
background to the studies being reported should be included in all manuscripts in the 
Materials and Methods section. Ethics committee or institutional review board approval should 
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Patients have a right to privacy that should not be infringed without informed consent. 
Identifying information should not be published in written descriptions, photographs and 
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